Loading
A phase 2 trial of CAR-T-19 cell injection in acute lymphoblastic leukaemia, run by Beijing Yongtai Ruike Biotechnology Company Ltd, now recruiting.
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL is a phase 2 interventional study registered as NCT06179524 by Beijing Yongtai Ruike Biotechnology Company Ltd, with 100 participants planned, started 2024-01-03 and due to reach its primary completion in 2025-06-30. Interventions recorded: CAR-T-19 cell injection.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.